Action of Varespladib (LY-315920), a Phospholipase A(2) Inhibitor, on the Enzymatic, Coagulant and Haemorrhagic Activities of Lachesis muta rhombeata (South-American Bushmaster) Venom

Varespladib (VPL) was primarily developed to treat inflammatory disturbances associated with high levels of serum phospholipase A(2) (PLA(2)). VPL has also demonstrated to be a potential antivenom support agent to prevent PLA(2)-dependent effects produced by snake venoms. In this study, we examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutierres, Pamella G., Pereira, Diego R., Vieira, Nataly L., Arantes, Lilian F., Silva, Nelson J., Torres-Bonilla, Kristian A., Hyslop, Stephen, Morais-Zani, Karen, Nogueira, Rosa M. B., Rowan, Edward G., Floriano, Rafael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790531/
https://www.ncbi.nlm.nih.gov/pubmed/35095526
http://dx.doi.org/10.3389/fphar.2021.812295

Ejemplares similares

Ejemplares similares